This is an entirely free service. No payments are to be made. Also send me The Ultimate Guide to Profiting From Derivatives and sign me up for Profit Hunter,a free newsletter that focuses on identifying short term money making opportunities.Download NowSubscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

More on ASTRAZENECA PHARMA

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... Morecare, oncology, infection, and pain control & anaesthesia. The company benefits from its parent's strong pipeline novel products. In fact, the UK parent is recognised as having one of the best development pipelines in the industry and spends over U$ 14 m each working day to maintain a flow of new medicines. The R&D facility in India has more than 90 scientists of international repute. AstraZeneca is the only pharmaceutical company with a research programme in India totally dedicated to TB. During the period between CY02 and CY05, the company grew its revenues and net profits at compounded rates of 19% and 61% respectively.

CADILA HEALTHCARE

More on CADILA HEALTHCARE

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... Moreket and also focusing on contract manufacturing. On the contract manufacturing front, Cadila has signed a deal with Abbott for supply of deugs inemerging markets. Cadila also has a JV with Nycomed as well as with Hospira. In FY09, Cadila demerged its consumer healthcare business into a separate listed company called Zydus Wellness Ltd. The company since then has made acquisitions such as Nesher Pharma (US), Biochem (domestic business) and Bremer Pharma (animal health).

OTHER USEFUL LINKS

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.